The Past, Present and Future of Venetoclax Plus Hypomethylating Agent Combination Therapies in AML
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Past, Present and Future of Venetoclax Plus Hypomethylating Agent Combination Therapies in AML
Authors
Keywords
Azacitidine, BCL2 and relapsed/refractory, Leukemia stem cells, Targeted therapies
Journal
Clinical Lymphoma Myeloma & Leukemia
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-07-19
DOI
10.1016/j.clml.2021.07.012
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Decitabine and venetoclax for IDH1/2 ‐ mutated acute myeloid leukemia
- (2021) Sangeetha Venugopal et al. AMERICAN JOURNAL OF HEMATOLOGY
- Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax
- (2021) Marina Y. Konopleva BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
- (2021) Vinod A. Pullarkat et al. Cancer Discovery
- Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
- (2021) Matthew E. Tenold et al. Frontiers in Oncology
- Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
- (2021) Maximilian Stahl et al. Blood Advances
- Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14)
- (2021) Hareth Nahi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
- (2021) Naseema Gangat et al. AMERICAN JOURNAL OF HEMATOLOGY
- Intact TP53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
- (2021) Rachel Thijssen et al. BLOOD
- Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production
- (2021) JongBok Lee et al. BLOOD
- Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine
- (2021) Ralf Buettner et al. Journal of Hematology & Oncology
- Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax
- (2021) Curtis A. Lachowiez et al. Blood Advances
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
- (2020) Courtney D. DiNardo et al. BLOOD
- Targeting MCL-1 in hematologic malignancies: Rationale and progress
- (2020) AndrewH. Wei et al. BLOOD REVIEWS
- 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-mediated Apoptosis.
- (2020) Sha Jin et al. CLINICAL CANCER RESEARCH
- Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience
- (2020) Daria Gaut et al. LEUKEMIA RESEARCH
- Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients
- (2020) Shanshan Pei et al. Cancer Discovery
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells
- (2020) Courtney L. Jones et al. Cell Stem Cell
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
- (2020) Courtney D DiNardo et al. Lancet Haematology
- Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia
- (2020) Shruti Bhatt et al. CANCER CELL
- Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax
- (2020) Mario L. Marques-Piubelli et al. LEUKEMIA & LYMPHOMA
- The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML
- (2019) Le Xuan Truong Nguyen et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity
- (2019) Kevin H. Lin et al. Cell Metabolism
- Venetoclax-based Therapies for Acute Myeloid Leukemia
- (2019) Veronica A. Guerra et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
- (2019) Lina Han et al. HAEMATOLOGICA
- Targeting mitochondrial structure sensitizes acute myeloid leukemia to Venetoclax treatment
- (2019) Xufeng Chen et al. Cancer Discovery
- The TP53 Apoptotic Network is a Primary Mediator of Resistance to BCL2 inhibition in AML Cells
- (2019) Tamilla Nechiporuk et al. Cancer Discovery
- Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents—a multicenter historical prospective study
- (2019) Ron Ram et al. ANNALS OF HEMATOLOGY
- Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
- (2019) Heikki Kuusanmäki et al. HAEMATOLOGICA
- Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling
- (2019) Felix Seyfried et al. Cell Death & Disease
- Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response
- (2019) David Sharon et al. Science Translational Medicine
- Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
- (2018) Ibrahim Aldoss et al. HAEMATOLOGICA
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
- (2018) Courtney D DiNardo et al. LANCET ONCOLOGY
- Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
- (2018) Ibrahim Aldoss et al. HAEMATOLOGICA
- BCL-2 inhibition in AML: an unexpected bonus?
- (2018) Marina Konopleva et al. BLOOD
- Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1
- (2018) Daniel A. Luedtke et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- A Novel MCL-1 Inhibitor Combined with Venetoclax Rescues Venetoclax Resistant Acute Myelogenous Leukemia
- (2018) Haley E. Ramsey et al. Cancer Discovery
- Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells
- (2018) Courtney L. Jones et al. CANCER CELL
- Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia
- (2018) Daniel A. Pollyea et al. NATURE MEDICINE
- Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia
- (2018) Piers Blombery et al. Cancer Discovery
- Tracing the origins of relapse in acute myeloid leukaemia to stem cells
- (2017) Liran I. Shlush et al. NATURE
- Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax
- (2017) Joel D. Leverson et al. Cancer Discovery
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia
- (2016) Kevin H. Lin et al. Scientific Reports
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs
- (2015) Jo Ishizawa et al. PLoS One
- BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
- (2013) Eleni D. Lagadinou et al. Cell Stem Cell
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia
- (2012) M. S. Davids et al. BLOOD
- Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
- (2010) H. Kantarjian et al. BLOOD
- A comparison of gene expression profiles between primary human AML cells and AML cell line
- (2008) Jinseok Lee et al. GENES & GENETIC SYSTEMS
- Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia
- (2008) J A Kennedy et al. LEUKEMIA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now